Polymeric Conjugates of Selected Aminoquinoline Derivatives as Potential Drug Adjuvants in Cancer Chemotherapy

In the chemotherapy of cancerous diseases, the clinical co-administration of an active anti-tumor drug with other compounds acting as potentiating agents or adjuvants has demonstrated considerable merits in comparison with single-drug administration. Selected members of the 4- and 8-aminoquinoline-based class of antimalarials, such as chloroquine and hydroxychloroquine, have been identified as providers of such adjuvant effects in combination with certain standard antitumor drugs, although no significant clinical experiences have as yet been reported. The here described project aims at the synthesis of water-soluble macromolecular carriers to which selected aminoquinolines are bioreversibly conjugated together with cytotoxic drug species exemplified by a diaminoplatinum(II) complex and by the organoiron compound, ferrocene, the latter being a relative newcomer to the family of organometallic antineoplastic agents. As most medicinal agents differ from each other by their pharmacokinetic path and, therefore, experience different rates and degree of body distribution and organ accumulation, the simultaneous availability of two or more mutually potentiating drug species can best be achieved if a common transport vehicle, such as a multifunctional carrier polymer of the type synthesized in this study, is utilized for this purpose. The conjugates and co-conjugates, isolated by conventional methods as water-soluble solids, are compositionally characterized by NMR-spectroscopic and microanalytical techniques.     

Design and synthesis of polysapartamide co-drugs of platinum and methotrexate as anticancer agents

Literature reports several recent attempts to load a single drug onto one carrier to improve drug efficacy. An ideal anticancer drug would result from anchoring two anticancer drugs on a single carrier to exploit the advantage of possible synergistic interactions between the drugs, whilst targeting different sites in the cancer cell. This work presents the results of the synthesis and analysis of water-soluble polyaspartamide carriers, which were loaded with platinum along with methotrexate. Platinum was anchored by coordination and methotrexate by amide bonds. In all cases, drug incorporation in the molecule was assessed to be 100%. NMR was used for methotrexate conjugate analysis, while platinum incorporation was evaluated by CHN analysis. The in vitro antiproliferative activity against breast cancer displayed a very good cytotoxic activity by the co-conjugates over the free drugs and their simple conjugates.     

Polymers with platinum drugs and other macromolecular metal complexes for cancer treatment

Metal-based anticancer drugs, in particular platinum-drugs, have been investigated for the treatment of cancer for the last 40 years. A small set of platinum-based drugs have meanwhile received FDA approval for the treatment of various cancer. Cisplatin and its relatives are currently one of the most widely used anticancer drugs. The use is however associated with significant side effects and rising drug resistance. To combat these problems, drug delivery carriers have been developed to increase the protection of the drug and increase efficacy. Metal-based drugs represent a rather unique drug delivery challenge. Most anticancer drugs are either physically encapsulated into a polymer matrix or they can be conjugated to the polymer via a degradable linker. While both pathways are possible for metal-based drugs, the conjugation to the polymer can be carried via labile or permanent ligands. In addition, the prodrug strategy using the drug in the higher oxidation state is a common approach that has been widely tested for platinum drug. The delivery of platinum drugs is now a mature field and the various conjugation techniques have been combined with a range of drug carriers including dendrimers, micelles and solid polymer nanoparticles. Hybrids of macromolecular metal complexes with inorganic nanoparticles have been tested in recent years to combine the ability to deliver the drug with imaging properties. An emerging trend is the surface decoration of the polymeric nanoparticles with targeting ligands such as folates. The advanced state of this field is evident by the fact that some macromolecular platinum drugs even advanced to the clinic. While the delivery of platinum drugs has been well explored, the delivery of other metal-based drugs based on gold, ruthenium or cobalt is still in their infancy.     

Water-Soluble Polymer–Ferrocene Conjugates Based on Polyamide Carriers Containing Intrachain-Type Secondary Amine Functions as Binding Sites

It is the objective of this project to synthesize polymer–ferrocene conjugates from macromolecular carriers in which the anchoring sites are main-chain constituents, thus contrasting with previously described conjugates featuring side-chain terminals as anchoring sites. To this end, earlier-developed polyamide carriers containing secondary amino groups in the main chain are treated with the active N-succinimidyl ester of 4-ferrocenylbutanoic acid in DMF solution. Molar feed ratios are chosen so as to favor the incorporation of a single ferrocenyl group per recurring unit. The water-soluble, microanalytically and spectroscopically characterized conjugates are of interest as antiproliferative agents in cancer research.     

Prodrug strategies in anticancer chemotherapy

The majority of clinically approved anticancer drugs are characterized by a narrow therapeutic window that results mainly from a high systemic toxicity of the drugs in combination with an evident lack of tumor selectivity. Besides the development of suitable galenic formulations such as liposomes or micelles, several promising prodrug approaches have been followed in the last decades with the aim of improving chemotherapy. In this review we elucidate the two main concepts that underlie the design of most anticancer prodrugs: drug targeting and controlled release of the drug at the tumor site. Consequently, active and passive targeting using tumor-specific ligands or macromolecular carriers are discussed as well as release strategies that are based on tumor-specific characteristics such as low pH or the expression of tumor-associated enzymes. Furthermore, other strategies such as ADEPT (antibody-directed enzyme prodrug therapy) and the design of self-eliminating structures are introduced. Chemical realization of prodrug approaches is illustrated by drug candidates that have or may have clinical importance.     

Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol

Lipid nanoparticles are currently used to deliver drugs to specific sites in the body, known as targeted therapy. Conjugates of lipids and drugs to produce drug-enriched phospholipid micelles have been proposed to increase the lipophilic character of drugs to overcome biological barriers. However, their applicability at the topical level is still minimal. Phospholipid micelles are amphiphilic colloidal systems of nanometric dimensions, composed of a lipophilic nucleus and a hydrophilic outer surface. They are currently used successfully as pharmaceutical vehicles for poorly water-soluble drugs. These micelles have high in vitro and in vivo stability and high biocompatibility. This review discusses the use of lipid-drug conjugates as biocompatible carriers for cutaneous application. This work provides a metadata analysis of publications concerning the conjugation of cannabidiol with lipids as a suitable approach and as a new delivery system for this drug.     

Water-Soluble Macromolecular Platinum Conjugates Derived from 1,2-Dihydroxyl-Functionalized Carrier Polymers

The class of platinum-containing bioactive agents, including cisplatin as the prototype, and structurally related second- and third-generation compounds, has developed during the past two decades as one of the most important family of antitumor drugs. However, despite a highly valued general antineoplastic performance profile, their unrestricted oncological administration continues to be hampered by pharmacological shortcomings, notably excessive toxicity and induction of drug resistance. This has prompted ongoing intensive development activities in pharmaceutic laboratories worldwide, and one of the most promising approaches emanating from these activities involves the drug conjugation to biomedically functional, water-soluble carrier polymers. Such macromolecular conjugates, judiciously designed and synthesized, provide significant pharmacological advantages over non-polymeric drug systems, notably increased cell specificity and facilitated cell entry, paired with reduced toxicity and resistance problems. In the present project, this technology has been applied specifically to the synthesis of Pt-containing polymers in which the metal is carrier-bound via dihydroxylatoplatinum chelation. In the cancerous target cell, such conjugates will deliver the free bioactive Pt complex hydrolytically for its cytotoxic action. The water-soluble polymeric products, fractionated by dialysis in membrane tubing with molecular-mass cut-off of 25,000, will be submitted to an outside institution for in vitro evaluation of cytotoxic properties.     

Carrier‐bound methotrexate. I. Water‐soluble polyaspartamide–methotrexate conjugates with ester links in the polymer–drug spacer

The antifolate‐type anticancer drug methotrexate (MTX) has for many years, in numerous laboratories, been a “workhorse” drug for conjugation with natural and synthetic macromolecular carriers for the purpose of enhancing bioavailability and lowering toxic side effects. In the project here described the polymer–drug conjugation strategy is utilized for the preparation of water‐soluble polyaspartamide–methotrexate conjugates in which the drug is carrier‐anchored through short spacers containing ester groups as biofissionable links. To this end, polyaspartamide carriers 1, poly‐α,β‐D,L ‐N‐(2‐hydroxyethyl)aspartamide, and 2, poly‐α,β‐D,L ‐N‐[2‐(2‐hydroxyethoxy)ethyl]aspartamide, are treated with MTX in DMF solution in the presence of a carbodiimide coupling agent and 4‐(dimethylamino)pyridine catalyst. The molar MTX/OH feed ratios, 0.28 and lower, are chosen in these coupling reactions so as to provide conjugates featuring drug‐loading levels in the approximate range of 3–16 mol % MTX, roughly corresponding to 6–28% by mass. The water‐soluble product polymers are purified by aqueous dialysis, collected in the solid state by freeze‐drying, and structurally characterized by ¹H–NMR spectroscopy. © 2001 John Wiley & Sons, Inc. J Appl Polym Sci 82: 1844–1849, 2001     

Nanoarchitectonics: Complexes and Conjugates of Platinum Drugs with Silicon Containing Nanocarriers. An Overview

The development in the area of novel anticancer prodrugs (conjugates and complexes) has attracted growing attention from many research groups. The dangerous side effects of currently used anticancer drugs, including cisplatin and other platinum based drugs, as well their systemic toxicity is a driving force for intensive search and presents a safer way in delivery platform of active molecules. Silicon based nanocarriers play an important role in achieving the goal of synthesis of the more effective prodrugs. It is worth to underline that silicon based platform including silica and silsesquioxane nanocarriers offers higher stability, biocompatibility of such the materials and pro-longed release of active platinum drugs. Silicon nanomaterials themselves are well-known for improving drug delivery, being themselves non-toxic, and versatile, and tailored surface chemistry. This review summarizes the current state-of-the-art within constructs of silicon-containing nano-carriers conjugated and complexed with platinum based drugs. Contrary to a number of other reviews, it stresses the role of nano-chemistry as a primary tool in the development of novel prodrugs.     

Cytotoxicity of Selected Water-Soluble Polymer–cis-Diaminedichloroplatinum(II) Conjugates Against the Human HeLa Cancer Cell Line

Several polymer-platinum conjugates comprising the square-planar cis-diaminedichloroplatinum(II) complex system of cisplatin-type anticancer drugs are screened for antiproliferative activity in cell culture tests. The water-soluble conjugates prepared in this study or taken from preceding investigations are obtained by platination of aliphatic polyamide carriers containing ethylenediamine segments as side-group or main-chain components. These segments, coordinating to the metal as cis-diamine chelating ligands, are bound to, or into, the carrier backbone through biofissionable amide links permitting drug release from the carrier. In vitro tests are performed against a HeLa human cervix carcinoma cell line. IC₅₀ data, expressed as the concentration of Pt in the conjugates (μg/ml), causing 50% inhibition of cell growth, show the highest activity, with IC₅₀=14 μg/ml, to be associated with a conjugate derived from a polyaspartamide carrier that contains the platinum complex as a side group in proximity to the main chain and, additionally, contains dimethylaminopropyl side groups as solubilizing functions. At the low end of the performance spectrum is a conjugate, with IC₅₀>120 μg/ml, possessing a similar backbone and metal-binding structure, yet comprising long poly(ethylene oxide) grafts. The latter apparently shield the complex-binding tether from enzymatic attack and thus prevent efficient intracellular release of the monomeric complex. Selected conjugates will be submitted for toxicological evaluation.     

Targeted cancer therapy: conferring specificity to cytotoxic drugs

The therapeutic activity of most anticancer drugs in clinical use is limited by their general toxicity to proliferating cells, including some normal cells. Although, chemists continue to develop novel cytotoxic agents with unique mechanisms of action, many of these compounds still lack tumor selectivity and have not been therapeutically useful. Monoclonal antibodies that bind to specific markers on the surface of tumor cells offer an alternative therapy that is tumor specific and thus less toxic. Although highly selective, very few monoclonal antibodies are therapeutically useful since they only display modest cell killing activity. The linkage of monoclonal antibodies to highly cytotoxic drugs can be viewed as a means of (a) conferring higher tumor selectivity to cytotoxic drugs that are too toxic to be used on their own or (b) conferring cell killing power to monoclonal antibodies that are tumor-specific but not sufficiently cytotoxic. This Account provides a brief history of the development of antibody-drug conjugates and shows how the lessons learned from the first generation of conjugates has guided the development of more effective antitumor agents. The three components of antibody-drug conjugates, that is, the monoclonal anitbody, the cytotoxic drug, and the linker connecting the drug to the antibody, have been methodically studied and optimized. The antimitotic drug maytansine was chosen for use in the targeted delivery approach because of its high in vitro potency. Analogues of maytansine bearing a disulfide substituent that allowed linkage to monoclonal antibodies via disulfide bonds were prepared. These analogues retain the high potency of the parent drug. The stability of the disulfide link in antibody-maytansinoid conjugates was varied by introduction of methyl substituents on the carbon atoms geminal to the disulfide link. The optimized disulfide linker was stable in circulation in vivo. The circulation half-life of the cytotoxic drug was increased from just a few hours for the unconjugated drug to several days for the conjugate. Upon binding of the conjugate to the tumor cell, internalization and lysosomal processing released the potent cytotoxic agent inside the cell. These conjugates displayed high target-specific cytotoxicity in vitro. The antitumor activity of these targeted agents was superior to that of the antibodies alone or the standard anticancer drugs in human tumor xenograft models. Several conjugates from this new class of tumor-targeted anticancer agents are currrently undergoing clinical evaluation. The progress made in the targeted delivery approach and initial clinical results opens the door to the future development of highly potent drugs that were too toxic on their own to be therapeutically useful.     

Evaluation of Floxuridine Oligonucleotide Conjugates Carrying Potential Enhancers of Cellular Uptake

Conjugation of small molecules such as lipids or receptor ligands to anti-cancer drugs has been used to improve their pharmacological properties. In this work, we studied the biological effects of several small-molecule enhancers into a short oligonucleotide made of five floxuridine units. Specifically, we studied adding cholesterol, palmitic acid, polyethyleneglycol (PEG 1000), folic acid and triantennary N-acetylgalactosamine (GalNAc) as potential enhancers of cellular uptake. As expected, all these molecules increased the internalization efficiency with different degrees depending on the cell line. The conjugates showed antiproliferative activity due to their metabolic activation by nuclease degradation generating floxuridine monophosphate. The cytotoxicity and apoptosis assays showed an increase in the anti-cancer activity of the conjugates related to the floxuridine oligomer, but this effect did not correlate with the internalization results. Palmitic and folic acid conjugates provide the highest antiproliferative activity without having the highest internalization results. On the contrary, cholesterol oligomers that were the best-internalized oligomers had poor antiproliferative activity, even worse than the unmodified floxuridine oligomer. Especially relevant is the effect induced by palmitic and folic acid derivatives generating the most active drugs. These results are of special interest for delivering other therapeutic oligonucleotides.     

Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines

Cell-penetrating peptides (CPPs) are small peptide sequences used mainly as cellular delivery agents that are able to efficiently deliver cargo into cells. Some CPPs also demonstrate intrinsic anticancer properties. Previously, our group developed a new family of CPP2-thiazole conjugates that have been shown to effectively reduce the proliferation of different cancer cells. This work aimed to combine these CPP2-thiazole conjugates with paclitaxel (PTX) and 5-fluorouracil (5-FU) in PC-3 prostate and HT-29 colon cancer cells, respectively, to evaluate the cytotoxic effects of these combinations. We also combined these CPP2-thiazole conjugates with clotrimazole (CLZ), an antifungal agent that has been shown to decrease cancer cell proliferation. Cell viability was evaluated using MTT and SRB assays. Drug interaction was quantified using the Chou–Talalay method. We determined that CPP2 did not have significant activity in these cells and demonstrate that N-terminal modification of this peptide enhanced its anticancer activity in both cell lines. Our results also showed an uneven response between cell lines to the proposed combinations. PC-3 cells were more responsive to the combination of CPP2-thiazole conjugates with CLZ than PTX and were more sensitive to these combinations than HT-29 cells. In addition, the interaction of drugs resulted in more synergism in PC-3 cells. These results suggest that N-terminal modification of CPP2 results in the enhanced anticancer activity of the peptide and demonstrates the potential of CPPs as adjuvants in cancer therapy. These results also validate that CLZ has significant anticancer activity both alone and in combination and support the strategy of drug repurposing coupled to drug combination for prostate cancer therapy.     

Macromolecular Antiproliferative Agents Featuring Dicarboxylato-Chelated Platinum

Cancerous diseases, together with cardiac afflictions, account for the predominant causes of death among the adult population of the Western world. The classical platinum drugs, with cisplatin as their parent, have established themselves for years as leading components in the oncologist’s arsenal of antitumor agents. As with most other antineoplastic drugs, however, incisive pharmacological deficiencies, notably excessive systemic toxicity and induction of drug resistance, have severely curtailed their overall efficaciousness. With the objective of overcoming these counterproductive deficiencies, the technique of polymer-drug conjugation, representing an advanced modality of drug delivery, has been developed in recent years to high standards worldwide. In a drug conjugate, water-soluble macromolecular carrier constructs designed in compliance with stringent pharmacological specifications are covalently, yet bioreversibly, interconnected with the bioactive agent. As a macromolecule following a pharmacokinetic pathway different from that of non-polymeric compounds, the conjugate acts as a pro-drug favorably transporting the agent through the various body compartments to, and into, the target cell, where the agent is enzymatically or hydrolytically separated from the carrier for its biological action. In the authors’ laboratories the conjugation strategy has been adopted as the primary tool for drug efficacy enhancement. The present paper describes a special type of platinum complex carrier-bound via dicarboxymetal chelation, synthesized from carboxyl-functionalized polyamide-type carriers by platination with trans-1,2-diaminocyclohexanediaquaplatinum(II) dinitrate. In a series of in vitro tests antiproliferative activities have been determined against several human cancer cell lines. Whereas no improvements are observed in tests against a colorectal cancer, outstanding findings of the screening program include a 10- to 100-fold increase in cell-killing performance of the conjugates relative to the (non-polymeric) cisplatin standard against the HeLa adenocarcinoma, and distinctly reduced resistance factors (again, relative to cisplatin) in tests against the A2780 and A2780-cis pair of ovarian cell lines. These findings augur well for future developments of this class of platinum drugs. This article is dedicated to Professor Astruc.     

A Water-Soluble Polyamide Containing <Emphasis Type="Italic">cis</Emphasis>-dicarboxylato-chelated Platinum(II)

For use as a macromolecular drug carrier in the development of carrier-bound platinum anticancer drugs, the water-soluble polyamides 1 and 2 have been synthesized, meeting the specific structural requirement of the presence of pairs of carboxyl groups directly attached to the polymer main chain in 1,1geometry. The synthesis involves solution polymerization of diamines with the key monomer, 2,2-bis(2-methoxycarbonylethyl)malonic acid (6), prepared from diethyl malonate via several intermediary malonic acid derivatives. The diamine monomers are 1,3-diaminopropane and 4,7,10-trioxa-1,13-tridecanediamine, leading, respectively, to the polyamides 1 and 2. The polymerization proceeds in the presence of anhydrous sodium carbonate. Rigorous purification by precipitation, reprecipitation, and aqueous dialysis, followed by freeze-drying, furnishes the target compounds as water-soluble, solid polymers, which are structurally characterized by spectroscopic and microanalytical techniques. The exemplifying platination of carrier 2 with DACH-Pt (trans-1,2-diaminocyclohexanediaquaplatinum(II) dinitrate) provides the conjugate 2-Pt as a water-soluble compound with a Pt content of 8%.     

Aliphatic polyamides prepared by ester-amine polycondensation as potential drug carrier polymers

Aliphatic polyamides of interest as macromolecular drug carriers are synthesized by base-catalyzed polycondensation of aliphatic diesters with diamines. The reactions are conducted in the presence of anhydrous sodium carbonate at temperatures ranging from ambient to 65°C, initially in the undilute state. The addition of aprotic solvent at a later stage serves to maintain sufficiently low viscosity for proper homogenization. The comonomers, diethyl 3,6,9-trioxaundecanedioate and 4,7,10-trioxa-1,13-tridecanediamine, copolymerize to form polymer 1, a straight-chain polyamide devoid of specific functionality. Use of diethyl tartrate in lieu of the aforementioned diester leads to polyamide 2 possessing hydroxyl side groups. Other experiments in which diamines incorporating additional (secondary) amino groups are employed afford polyamides 3–8 containing such secondary amine functions as main-chain constituents. The water-soluble target polymers are crudely fractionated by aqueous dialysis (12000–14000 molecular mass cut-off) and collected by freeze-drying in yields of 20 to 40%. The low-yield range has been accepted in this investigation as the price to be paid for the realization of linear polyamide structures in accordance with compositional expectations, a requirement vital for the proper functioning of the polymers as drug carriers. The practicability of drug binding (conjugating) is exemplified by the coupling of ferrocene as a drug model to polyamide 5 via amide linkage. The water-soluble conjugate 5-Fc features an iron content corresponding to one ferrocene group in the repeat unit. © 1999 John Wiley & Sons, Inc. J Appl Polym Sci 73: 2143–2150, 1999     

Polymer–Ferrocene Conjugates Containing an Ester Function in the Connecting Links

Ferrocene, the parent of the metallocene family of organotransition metal compounds, has come to occupy a significant niche in cancer research. Developmental work in the authors' laboratory has been focused on the synthesis of antiproliferative ferrocene conjugates in which the bioactive ferrocene unit is covalently, yet bioreversibly bound (anchored) to water-soluble carrier polymers designed in accordance with requisite biomedical specifications. The anchoring link in most of these conjugates has been an aliphatic spacer containing the biofissionable amide group. In this communication the synthesis of a class of ferrocene conjugates is reported in which the ferrocene group is carrier-anchored through spacers containing an ester link, of interest here because of potentially different drug release behavior. The carriers are polyamides equipped with variously spaced hydroxyl side groups, to which the ferrocenylation agent, 4-ferrocenylbutanoic acid, is connected through esterification. The coupling reactions, mediated by carbodiimide agent and catalyzed by 4-(dimethylamino)pyridine, are carried out in DMF at temperatures not exceeding 65°C, and the water-soluble product polymers are isolated in yields of typically 70–85% by precipitation, aqueous dialysis, and freeze-drying. With the molar feed ratios chosen in these coupling experiments, the incorporation of ferrocene, assessed by ¹H NMR spectroscopy, corresponds to iron contents of roughly 2.5–5.5%, by mass. The conjugates will be included in a forthcoming bioactivity screening program.     

Polyphophazenes as anti-cancer drug carriers: From synthesis to application

Currently, most of administered anti-cancer drugs are low molecular weight compounds (as compare to polymers) and hydrophobic in nature. Such small molecular anti-cancer drugs possess fast clearance rate from the blood circulating system and have toxic side effects. Poly(organophosphazenes) have wide range of biomedical applications owing good biocompatibility, sustainability and degradability into non-toxic by-products. So, in this review, we have carefully selected such poly(organophosphazenes), which proved to be good anti-cancer drug carriers because of overcoming crucial issues related to the administration of anti-cancer drugs i.e. poor hydrophilicity, lack of cancer cells specificity, and fast clearance rate from blood circulating system. Thence, the main focus of this review is to highlight the advancement that have been achieved in the synthesis of poly(organophosphazenes) and their application in anti-cancer drug delivery system (DDS).     

cis-Diaminedichloroplatinum(II) complexes reversibly bound to water-soluble polyaspartamide carriers for chemotherapeutic applications. I. Platinum coordination to preformed,carrier-attached ethylenediamine ligands

Copolyaspartamides3–5, bearing the ethylenediamine (en) ligand as a repetitive side-chain component in addition to various hydrosolubilizing groups, are synthesized from polysuccinimide1 by a two-step aminolytic ring opening reaction. The completely water-soluble polyamides, possessing inherent viscosities of 5–20 ml g^?1, are used as polymeric carriers for the “anchoring” of the biomedically important diaminedichloroplatinum(II) coordination complex. Conjugate formation is brought about by treatment of the carriers with the tetrachloroplatinate(II) dianion in aqueous solution at pH 6.0 ± 0.5. The resulting, water-soluble conjugates3-Pt-5-Pt, purified by dialysis (12,000–14,000 molecular mass cutoff) and isolated in the solid state by freeze-drying from aqueous solution, possess platinum contents in the typical range of 15–25%. The metal is bound as acis-dichloro-en-Pt(II) complex to the polymer main chain via a short spacer segment incorporating a biofissionable amide link suitable forin vivo release of the complex. The conjugates are of interest as water-soluble macromolecular platinum coordination compounds for potential use in the chemotherapy of cancerous diseases.     

Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads

A long-standing problem in cancer chemotherapy is the lack of tumor-specific treatments. Traditional chemotherapy relies on the premise that rapidly proliferating cancer cells are more likely to be killed by a cytotoxic agent. In reality, however, cytotoxic agents have very little or no specificity, which leads to systemic toxicity, causing undesirable severe side effects. Therefore, the development of innovative and efficacious tumor-specific drug delivery protocols or systems is urgently needed. A rapidly growing tumor requires various nutrients and vitamins. Thus, tumor cells overexpress many tumor-specific receptors, which can be used as targets to deliver cytotoxic agents into tumors. This Account presents our research program on the discovery and development of novel and efficient drug delivery systems, possessing tumor-targeting ability and efficacy against various cancer types, especially multidrug-resistant tumors. In general, a tumor-targeting drug delivery system consists of a tumor recognition moiety and a cytotoxic warhead connected directly or through a suitable linker to form a conjugate. The conjugate, which can be regarded as a "guided molecular missile", should be systemically nontoxic, that is, the linker must be stable in blood circulation, but upon internalization into the cancer cell, the conjugate should be readily cleaved to regenerate the active cytotoxic warhead. These novel "guided molecular missiles" are conjugates of the highly potent second-generation taxoid anticancer agents with tumor-targeting molecules through mechanism-based cleavable linkers. These conjugates are specifically delivered to tumors and internalized into tumor cells, and the potent taxoid anticancer agents are released from the linker into the cytoplasm. We have successfully used omega-3 polyunsaturated fatty acids, in particular DHA, and monoclonal antibodies (for EGFR) as tumor-targeting molecules for the conjugates, which exhibited remarkable efficacy against human tumor xenografts in animal models. We have developed self-immolative disulfide linkers wherein the glutathione-triggered cascade drug release takes place to generate the original anticancer agent. The use of disulfide linkers is attractive beacuse it takes into account the fact that the concentration of glutathione is much higher (>1000 times) in tumor cells than in blood plasma. In order to monitor and elucidate the mechanism of tumor-targeting, internalization, and drug release, several fluorescent and fluorogenic probes using biotin as the tumor-targeting module were developed and used. Then, the progressive occurrence of the designed receptor-mediated endocytosis, drug release, and drug binding to the target protein (microtubules) has been successfully observed and confirmed by means of confocal fluorescence microscopy. These "guided molecular missiles" provide bright prospects for the development of highly efficacious new generation drugs for cancer chemotherapy.